Dr. Matthew Fuchter

Biography

Matt Fuchter is a Professor of Chemistry at the University of Oxford and the Sydney Bailey Fellow in Chemistry at St Peter’s College, Oxford. He runs a multidisciplinary research group with a broad array of interests in functional molecules, materials, and medicines. His fundamental research has significantly contributed to the development of chiral materials for optoelectronic applications and photoswitchable molecules with diverse functional applications. In translational research, he is an inventor of drugs such as Samuraciclib (APL-4098) which are undergoing clinical trials for cancer therapy. He is the Founder and Non-Executive Director of NK:IO Ltd, an immune-oncology spinout company. Matt completed his PhD at Imperial College London under the supervision of Professor G. M. Barrett, FRS FMedSci in 2006, followed by postdoctoral studies at the Commonwealth Scientific and Industrial Research Organisation in Australia, working with Professor B. Holmes, AC FRS FAA FInstP in 2007. He was appointed RCUK Academic Fellow at the School of Pharmacy (University of London) before taking a Lectureship at Imperial College London, where he was promoted to Senior Lecturer in 2012, Reader in 2015, and Professor in 2018. In 2024, he moved to his current position at the University of Oxford. Matt has received several awards for his work, including the Royal Society of Chemistry Harrison-Meldola Memorial Prize in 2014, the 2018 Tetrahedron Young Investigator Award in Bioorganic Medicinal Chemistry, the Blavatnik Award for Young Scientists in the United Kingdom in 2020, the Royal Society of Chemistry Corday-Morgan Prize in 2021, and the Royal Society of Chemistry Stephanie L. Kwolek Award in 2022. He has been a Fellow of the Royal Society of Chemistry since 2015 and was elected to the European Academy of Sciences in 2023.

Research Interests

Awards